Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 3, 2006, Pages 693-696

  Stass, Heino ^a   Rink, A D ^b   Delesen, H ^a   Kubitza, D ^a   Vestweber, K H ^b  

^a BAYER AG   (Germany)

^b Children's Hospital Leverkusen   (Germany)

Author keywords

Ascitic fluid; Complicated intra abdominal infections; Peritoneal cavity; Tissue distribution

Indexed keywords

MOXIFLOXACIN;

ABDOMINAL INFECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INFUSION; DRUG PENETRATION; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MEAN RESIDENCE TIME; PERITONEAL CAVITY; PERITONEAL FLUID LEVEL; PERITONEUM EXUDATE; PERITONITIS; SINGLE DRUG DOSE; SURGICAL DRAINAGE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ASCITIC FLUID; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PERITONEUM; PERITONITIS; QUINOLINES;

EID: 33747874516     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl305     Document Type: Article

References (10)

1. Edmiston CE, Krepel CJ, Seabrook GR et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48: 1012-6.
2. Goldstein EJC, Citron DM, Warren YA et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50: 379-81.
3. Thadepalli H, Chuah SK, Gollapudi S. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice. Chemotherapy 2004; 50: 76-80.
4. Wirtz M, Kleeff J, Swoboda S et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004; 53: 875-7.
5. Stass H, Dahloff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163-74.
6. Melnik G, Schwesinger WH, Dogolo LC et al. Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery. Am J Surg 1998; 176 Suppl 6A: 14-17S.
7. Schaumann R, Goldstein EJC, Forberg J et al. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol 2005; 54: 749-53.
8. Cisneros RL, Onderdonk AB. Efficacy of moxifloxacin monotherapy versus gatifloxacin monotherapy, piperacillin-tazobactam combination therapy, and clindamycin plus gentamicin combination therapy: An experimental study in a rat model of intra-abdominal sepsis induced by fluoroquinolone-resistant Bacteroides fragilis. Curr Ther Res 2005; 66: 222-9.
9. Malangoni MA, Song J, Herrington J et al. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244: 204-11.
10. Ball P, Stahlmann R, Kubin R et al. Safety profile of oral and intravenous moxifloxacin: Cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940-50.